Data to Discovery: Identification & Validation of Novel Targets Using AI

Data to Discovery: Identification & Validation of Novel Targets Using AI

Thursday, May 6, 2021 7:45 PM to 7:55 PM · 10 min. (Africa/Abidjan)

Information

Envisagenics’ proprietary drug discovery software platform, SpliceCore®, can repurpose RNA sequencing data to expand therapeutic pipelines, verify protein-drug interactions, and create additional insights for biopharmaceutical partners. Envisagenics integrates proprietary machine learning algorithms, High Performance Computing, and RNA splicing analytics to identify potential targets from its proprietary database of approximately 7 million RNA splicing variants. SpliceCore runs natively on Microsoft Azure, but it is compatible with all cloud service providers. SpliceCore also offers superior performance, analyzing up to 1,000 patient datasets in under 2 hours.

Envisagenics Envisagenics is an artificial intelligence driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing variants that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.  Envisagenics partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities. Envisagenics also has its own internally developed RNA therapeutic programs. Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a current resident of Johnson & Johnson Innovation – JLABS@NYC. Envisagenics is the proud recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute.  

Registered attendees

Abderrazak Chahid
Abderrazak Chahid
PostdocOntario Tech University
AN
Akira Namerikawa
MBA CandidateUniversity of Cambridge
AS
Ali Sahari
Staff Software EngineerAmyris

Log in